QIAGEN has presented its new high-throughput sample processing system at SLAS2026. 

The QIAsprint Connect marks the company’s entry into high-throughput sample processing, enabling preparation of up to 192 samples per run while reducing plastic consumption.  

QIAGEN hopes the system can address demand for automation and throughput in applications, in particular liquid biopsy, minimal residual disease testing and microbiome research. 

The new system is part of QIAGEN’s growth plan for 2026, released in January, which builds on the company’s acquisition of Parse Biosciences, expanding its sample technologies portfolio into single-cell analysis. 

“We delivered on key targets in 2025 and enter 2026 with strong momentum,” Thierry Bernard, CEO of QIAGEN, said in January.  

“Our investments we are making in automation, menu expansion and AI, together with targeted and differentiated acquisitions, are designed to accelerate growth, advancing in high-value areas of life sciences and diagnostics and sharpening our competitive edge as we move toward achieving our 2028 ambitions.”